Actos shows sustained efficacy over 2-year period.

Publication: Biotech Business Week

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 NewsRX

2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Long-term studies using the oral antidiabetic drug Actos (pioglitazone HCl) alone, and in combination with other oral antidiabetic medications, found that it provided sustained improvements in glycemic control, insulin sensitivity and key lipid parameters over a 104-week period.

The findings were presented at the American Diabetes Association's (ADA) 64th Annual Scientific Sessions.

"Given the clinical challenges of managing diabetes patients over time, and the fact that patients are living longer with diabetes, the data being presented on Actos help physicians better understand the drug's effectiveness over an extended period," said Mehmood Khan, MD, FACE, senior vice president for medical and...

Read the full article for free courtesy of your local library.